Silence Therapeutics (SLN) has released an update.
Silence Therapeutics has reported a loss after taxation of £15,562,000 for the three months ended June 30, 2024, indicating a deeper loss compared to £10,401,000 for the same period in 2023. The company’s operating loss also increased to £18,323,000, up from £11,457,000 year-over-year. Despite the losses, the balance sheet shows a significant cash and cash equivalents increase to £109,482,000, up from £54,031,000 at the end of December 2023.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.
